開能健康(300272.SZ):2022年研發費用6681萬元 佔營收比例4%
格隆匯5月18日丨開能健康(300272.SZ)召開業績説明會,就“公司2023年研發投入比例大概是多少?研發人員是否會增加?研發的主要方向是哪些??”
開能健康表示,2022年公司研發費用6681萬元,較上年增長22.40%,佔營業收入比例4%,研發人員增加了21.58%,公司在2023年將會繼續朝着既定的經營目標努力,在研發方面將進一步加強在中央淨水機、中央軟水機、飲水機、RO淨水機、控制閥、複合壓力容器的產品開發,提升新產品銷售佔比,保持技術領先。公司將增加研究項目比例,在一系列基礎技術上進行深入研究,包括過濾技術、控制閥、智能控制系統、物聯網技術等。公司將優化項目協同,提高快速定製類的項目響應速度。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.